IQSEC3

Summary

IQSEC3 (IQ motif and Sec7 domain ArfGEF 3, HGNC:29193) is a protein-coding gene on chromosome 12p13.33, encoding IQ motif and SEC7 domain-containing protein 3 (Q9UPP2). Acts as a guanine nucleotide exchange factor (GEF) for ARF1.

Predicted to enable guanyl-nucleotide exchange factor activity. Predicted to be involved in several processes, including activation of GTPase activity; postsynapse organization; and regulation of small GTPase mediated signal transduction. Located in cytosol and nucleoplasm.

Source: NCBI Gene 440073 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability (Moderate, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 183 total — 1 pathogenic
• MANE Select transcript: NM_001170738

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29193
Approved symbol	IQSEC3
Name	IQ motif and Sec7 domain ArfGEF 3
Location	12p13.33
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1110, MGC30156
Ensembl gene	ENSG00000120645
Ensembl biotype	protein_coding
OMIM	612118
Entrez	440073

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 2 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000382841, ENST00000537151, ENST00000538872, ENST00000540907, ENST00000544511

RefSeq mRNA: 2 — MANE Select: NM_001170738 NM_001170738, NM_015232

CCDS: CCDS31725, CCDS53728

Canonical transcript exons

ENST00000538872 — 14 exons

Exon	Start	End
ENSE00000893353	141124	141285
ENSE00000893355	157528	157694
ENSE00000893356	161926	162065
ENSE00000893357	163494	163619
ENSE00000893358	165434	165533
ENSE00000893359	165729	165890
ENSE00000893360	169013	169105
ENSE00001505730	125633	125912
ENSE00001671798	157025	157147
ENSE00002223867	174599	178455
ENSE00002310174	66767	67436
ENSE00003532902	99146	99214
ENSE00003573830	138267	139354
ENSE00003594037	171112	171161

Expression profiles

Bgee: expression breadth ubiquitous, 196 present calls, max score 98.62.

FANTOM5 (CAGE): breadth broad, TPM avg 0.5235 / max 46.6123, expressed in 194 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
123281	0.2182	77
123289	0.1731	106
123287	0.0843	45
123288	0.0478	25

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	98.62	gold quality
cerebellar hemisphere	UBERON:0002245	98.36	gold quality
cerebellar cortex	UBERON:0002129	98.33	gold quality
cerebellum	UBERON:0002037	97.14	gold quality
right frontal lobe	UBERON:0002810	96.81	gold quality
cingulate cortex	UBERON:0003027	94.84	gold quality
anterior cingulate cortex	UBERON:0009835	94.79	gold quality
amygdala	UBERON:0001876	94.35	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.29	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.27	gold quality
prefrontal cortex	UBERON:0000451	92.77	gold quality
frontal cortex	UBERON:0001870	92.25	gold quality
neocortex	UBERON:0001950	91.86	gold quality
cerebellar vermis	UBERON:0004720	91.31	gold quality
hypothalamus	UBERON:0001898	91.30	gold quality
nucleus accumbens	UBERON:0001882	91.26	gold quality
cerebral cortex	UBERON:0000956	90.92	gold quality
Ammon’s horn	UBERON:0001954	90.30	gold quality
telencephalon	UBERON:0001893	90.19	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.17	gold quality
brain	UBERON:0000955	90.06	gold quality
putamen	UBERON:0001874	89.92	gold quality
temporal lobe	UBERON:0001871	89.88	gold quality
central nervous system	UBERON:0001017	89.78	gold quality
forebrain	UBERON:0001890	89.73	gold quality
right uterine tube	UBERON:0001302	89.44	gold quality
lateral nuclear group of thalamus	UBERON:0002736	89.24	gold quality
caudate nucleus	UBERON:0001873	89.20	gold quality
postcentral gyrus	UBERON:0002581	88.91	gold quality
superior frontal gyrus	UBERON:0002661	88.33	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.25

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

220 targeting IQSEC3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6756-5P	99.82	67.97	2466

Literature-anchored findings (GeneRIF, showing 5)

• These results suggest that KIAA1110 is expressed specifically in mature neurons and may play an important role in the secretion pathway as a GEF for ARF1. (PMID:17981261)
• these data reveal that IQSEC3 acts together with gephyrin to regulate inhibitory synapse development. (PMID:27002143)
• The genomic and clinical landscape of fetal akinesia. (PMID:31680123)
• Loss of IQSEC3 Disrupts GABAergic Synapse Maintenance and Decreases Somatostatin Expression in the Hippocampus. (PMID:32049026)
• IQSEC3 Deletion Impairs Fear Memory Through Upregulation of Ribosomal S6K1 Signaling in the Hippocampus. (PMID:35219498)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	iqsec3b	ENSDARG00000093091
mus_musculus	Iqsec3	ENSMUSG00000040797
rattus_norvegicus	Iqsec3	ENSRNOG00000014083
drosophila_melanogaster	siz	FBGN0026179
drosophila_melanogaster	Sec71	FBGN0028538
drosophila_melanogaster	garz	FBGN0264560
caenorhabditis_elegans		WBGENE00007703
caenorhabditis_elegans		WBGENE00008685
caenorhabditis_elegans	agef-1	WBGENE00012386

Paralogs (15): CYTH3 (ENSG00000008256), PSD (ENSG00000059915), MON2 (ENSG00000061987), ARFGEF1 (ENSG00000066777), CYTH4 (ENSG00000100055), CYTH2 (ENSG00000105443), GBF1 (ENSG00000107862), CYTH1 (ENSG00000108669), ARFGEF2 (ENSG00000124198), IQSEC2 (ENSG00000124313), PSD4 (ENSG00000125637), IQSEC1 (ENSG00000144711), PSD2 (ENSG00000146005), PSD3 (ENSG00000156011), FBXO8 (ENSG00000164117)

Protein

Protein identifiers

IQ motif and SEC7 domain-containing protein 3 — Q9UPP2 (reviewed: Q9UPP2)

All UniProt accessions (1): Q9UPP2

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a guanine nucleotide exchange factor (GEF) for ARF1.

Subunit / interactions. Interacts with DLG1 and DLG4. Interacts with GPHN.

Subcellular location. Cytoplasm. Postsynaptic density.

Tissue specificity. Expressed specifically in the adult brain, predominantly in the cerebral cortex and the olfactory bulb, but not in the fetal brain. Expressed only in mature neurons, but not in undifferentiated neural stem precursor cells (NSPCs), nor in glioma cells.

Similarity. Belongs to the BRAG family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UPP2-1	1	yes
Q9UPP2-2	2

RefSeq proteins (2): NP_001164209, NP_056047 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000904	Sec7_dom	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR023394	Sec7_C_sf	Homologous_superfamily
IPR033742	IQSEC_PH	Domain
IPR035999	Sec7_dom_sf	Homologous_superfamily

Pfam: PF01369, PF16453

UniProt features (35 total): compositionally biased region 12, sequence conflict 6, region of interest 6, domain 3, splice variant 3, coiled-coil region 2, chain 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UPP2-F1	58.76	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 259

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-9768919	NPAS4 regulates expression of target genes
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9634815	Transcriptional Regulation by NPAS4

MSigDB gene sets: 124 (showing top): GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_DN, BROWNE_HCMV_INFECTION_48HR_DN, GOBP_REGULATION_OF_RECEPTOR_INTERNALIZATION, GOBP_REGULATION_OF_RECEPTOR_MEDIATED_ENDOCYTOSIS, GOBP_RECEPTOR_INTERNALIZATION, GOBP_REGULATION_OF_ENDOCYTOSIS, KEGG_ENDOCYTOSIS, GOBP_REGULATION_OF_TRANSPORT, GOBP_IMPORT_INTO_CELL, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_ENDOCYTOSIS, GOCC_POSTSYNAPSE

GO Biological Process (2): actin cytoskeleton organization (GO:0030036), regulation of ARF protein signal transduction (GO:0032012)

GO Molecular Function (1): guanyl-nucleotide exchange factor activity (GO:0005085)

GO Cellular Component (10): nucleoplasm (GO:0005654), cytosol (GO:0005829), postsynaptic density (GO:0014069), postsynaptic membrane (GO:0045211), inhibitory synapse (GO:0060077), glycinergic synapse (GO:0098690), GABA-ergic synapse (GO:0098982), postsynaptic specialization of symmetric synapse (GO:0099629), cytoplasm (GO:0005737), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Transcriptional Regulation by NPAS4	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
synapse	3
postsynaptic specialization	2
cytoskeleton organization	1
actin filament-based process	1
ARF protein signal transduction	1
regulation of small GTPase mediated signal transduction	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
nuclear lumen	1
cytoplasm	1
asymmetric synapse	1
synaptic membrane	1
postsynapse	1
symmetric synapse	1
intracellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

1376 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IQSEC3	GPHN	Q9NQX3	826
IQSEC3	RBFOX3	A6NFN3	825
IQSEC3	ARF6	P26438	735
IQSEC3	INSYN1	Q2T9L4	660
IQSEC3	ARF1	P10947	638
IQSEC3	ARHGEF9	O43307	568
IQSEC3	EVL	Q9UI08	515
IQSEC3	TMEM236	Q5W0B7	510
IQSEC3	RBM43	Q6ZSC3	482
IQSEC3	PLEK2	Q9NYT0	463
IQSEC3	NRIP2	Q9BQI9	463
IQSEC3	PLEK	P08567	451
IQSEC3	TEX52	A6NCN8	448
IQSEC3	NLGN2	Q8NFZ4	440
IQSEC3	RBMS3	Q6XE24	431
IQSEC3	INSYN2A	Q6ZSG2	431

IntAct

2 interactions, top by confidence:

A	B	Type	Score
M		psi-mi:“MI:0914”(association)	0.350

BioGRID (3): IQSEC3 (Affinity Capture-MS), IQSEC3 (Affinity Capture-RNA), IQSEC3 (Affinity Capture-MS)

ESM2 similar proteins: A0A140LI67, A0JN76, A1L2U9, A2A5N8, A2AJ77, A6QPM3, B1WAZ8, B8A5Y1, D3ZWK4, E9Q3T6, E9Q8T2, O15060, O88866, O94966, P0C2N6, P57058, Q05516, Q0IH98, Q0IJ29, Q3B725, Q3TES0, Q3UZD5, Q4R739, Q60760, Q68UT7, Q6NZK8, Q6P2A1, Q6P4K6, Q6Q783, Q6S5L9, Q6YND2, Q76M68, Q7ZWZ4, Q80X44, Q8BXX2, Q8N680, Q8NE63, Q96CK0, Q99592, Q9GZV8

Diamond homologs: A0A0G2JUG7, A2A5R2, A5PKW4, D4A631, E1JIT7, F1MUS9, F4IXW2, F4JN05, F4JSZ5, F4K2K3, G3X9K3, G5EET6, O08967, O13690, O13817, O43739, O46382, P11075, P34512, P39993, P47102, P63034, P63035, P97694, P97696, Q10491, Q15438, Q2KI41, Q2PFD7, Q3TES0, Q42510, Q54KA7, Q5DTT2, Q5DU25, Q5E9G6, Q5JU85, Q6DFZ1, Q6DN90, Q6P1I6, Q76M68

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

183 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	144
Likely benign	13
Benign	8

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1180524	GRCh37/hg19 12p13.33-13.31(chr12:189145-7730395)x3	Pathogenic

SpliceAI

3068 predictions. Top by Δscore:

Variant	Effect	Δscore
12:139350:AACAT:A	donor_gain	1.0000
12:139351:ACAT:A	donor_gain	1.0000
12:139352:CAT:C	donor_gain	1.0000
12:139352:CATG:C	donor_loss	1.0000
12:139353:AT:A	donor_gain	1.0000
12:139354:TGTA:T	donor_loss	1.0000
12:139355:G:GG	donor_gain	1.0000
12:141110:A:AG	acceptor_gain	1.0000
12:141111:C:G	acceptor_gain	1.0000
12:141116:A:AG	acceptor_gain	1.0000
12:141117:C:G	acceptor_gain	1.0000
12:141120:CCA:C	acceptor_loss	1.0000
12:141121:CAGA:C	acceptor_loss	1.0000
12:141122:A:AG	acceptor_gain	1.0000
12:141122:AGA:A	acceptor_loss	1.0000
12:141123:G:GT	acceptor_gain	1.0000
12:141123:GA:G	acceptor_gain	1.0000
12:141123:GAA:G	acceptor_gain	1.0000
12:141123:GAAA:G	acceptor_gain	1.0000
12:141123:GAAAC:G	acceptor_gain	1.0000
12:141282:TGGA:T	donor_gain	1.0000
12:141283:GGA:G	donor_gain	1.0000
12:141283:GGAG:G	donor_gain	1.0000
12:141284:GA:G	donor_gain	1.0000
12:141284:GAG:G	donor_gain	1.0000
12:141284:GAGT:G	donor_loss	1.0000
12:141285:AGT:A	donor_loss	1.0000
12:141286:G:C	donor_loss	1.0000
12:141286:G:GG	donor_gain	1.0000
12:141288:GAG:G	donor_loss	1.0000

AlphaMissense

7649 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:138328:T:A	I322N	1.000
12:138339:T:C	F326L	1.000
12:138340:T:C	F326S	1.000
12:138341:C:A	F326L	1.000
12:138341:C:G	F326L	1.000
12:138343:G:C	R327P	1.000
12:138355:T:C	L331P	1.000
12:139330:G:C	R656P	1.000
12:139335:G:C	G658R	1.000
12:139336:G:A	G658D	1.000
12:139339:T:C	L659P	1.000
12:139345:T:C	L661P	1.000
12:141137:G:C	G669R	1.000
12:141138:G:A	G669D	1.000
12:141150:T:C	L673P	1.000
12:141192:C:A	A687D	1.000
12:141198:T:C	F689S	1.000
12:141201:T:C	L690P	1.000
12:141204:T:C	L691P	1.000
12:141215:G:C	G695R	1.000
12:141219:T:C	L696P	1.000
12:141236:G:A	G702R	1.000
12:141236:G:C	G702R	1.000
12:141237:G:A	G702E	1.000
12:141246:T:C	L705P	1.000
12:141282:T:C	L717P	1.000
12:157075:T:C	L735P	1.000
12:157084:T:C	F738S	1.000
12:157132:T:C	L754P	1.000
12:157569:T:C	F773S	1.000

dbSNP variants (sampled 300 via entrez): RS1000005973 (12:124673 A>G,T), RS1000068705 (12:82069 T>C), RS1000076018 (12:82276 G>A), RS1000111387 (12:152755 C>T), RS1000156739 (12:144668 G>A), RS1000167210 (12:113955 A>C,G), RS1000218657 (12:178135 A>C), RS1000232719 (12:114156 G>A), RS1000236756 (12:128404 A>G), RS1000318306 (12:147778 C>T), RS1000405445 (12:157194 G>A), RS1000418167 (12:109216 C>T), RS1000421051 (12:142249 C>T), RS1000503249 (12:177228 A>G,T), RS1000600707 (12:148543 T>C)

Disease associations

OMIM: gene MIM:612118 | disease phenotypes: MIM:617468, MIM:208150

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability	Moderate	Autosomal recessive

Mondo (3): arthrogryposis multiplex congenita (MONDO:0015168), fetal akinesia deformation sequence 1 (MONDO:0100101), intellectual disability (MONDO:0001071)

Orphanet (2): Arthrogryposis multiplex congenita (Orphanet:1037), Fetal akinesia deformation sequence (Orphanet:994)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001520_1	Response to angiotensin II receptor blocker therapy	6.000000e-06
GCST002875_57	Diisocyanate-induced asthma	1.000000e-06
GCST007831_5	Anti-thyroglobulin (TgAb) levels in Hashimoto’s thyroiditis	4.000000e-06
GCST012020_445	Serum metabolite levels	8.000000e-23

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation	3
Benzo(a)pyrene	affects methylation, increases methylation	2
GSK-J4	decreases expression	1
bisphenol A	affects methylation, affects cotreatment, increases methylation	1
ethyl-p-hydroxybenzoate	decreases expression	1
dimethylselenide	increases expression, increases oxidation	1
mono-(2-ethylhexyl)phthalate	increases abundance, increases methylation	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Acetaminophen	decreases expression	1
Allergens	decreases expression	1
Diethylhexyl Phthalate	increases abundance, increases methylation	1
Lead	affects expression	1
Methapyrilene	increases methylation	1
Niclosamide	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Triclosan	increases expression	1
Aflatoxin B1	increases methylation	1
Reactive Oxygen Species	increases expression, increases oxidation	1

Clinical trials (associated diseases)

201 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders